Johnson & Johnson jumps as vaccine shipments to Europe set to resume after regulator says benefits outweigh blood clot risks

Johnson & Johnson shares climbed Tuesday as the drug maker restarts shipments of its coronavirus vaccine to the European Union.

View in browser Subscribe Business Insider brings you a personalized selection of our top business stories, every day. Was this email forwarded to you? Sign up for Business Insider here. Johnson & Johnson jumps as vaccine shipments to Europe set to resume after regulator says benefits outweigh blood clot risks Johnson & Johnson shares climbed Tuesday as the drug maker restarts shipments of its coronavirus vaccine to the European Union. READ MORE Premium 13 power players supercharging growth at DocuSign, the e-contracts company on an M&A streak From expanding market reach to developing new tech, these are some of the key execs driving hyper-growth at the e-signature platform. READ MORE Dropbox's HR chief dropped 5 hours of meetings a week she didn't need to be in after the company let workers organize their own days to be more productive Dropbox let staff re-organize their schedules to maximize productivity. International HR chief Laura Ryan realized hours of meetings had "just built up over time." READ MORE Premium Six crypto experts break down what was behind bitcoin's weekend flash crash — and share 7 charts and data points you need to watch when the price falls Six crypto experts break down what drove bitcoin's recent price drop and share the charts investors need to pay attention to when the price dips. READ MORE Winklevoss-backed crypto platform Gemini has more than doubled the assets it stores so far this year Winklevoss-backed crypto platform Gemini said its gains were linked to overall market growth and increased appetite from institutional investors. READ MORE Premium The growth lead at crypto exchange Kraken breaks down how Bitcoin's price might hit $1 million by the end of the year — and how Gen Z and millennials are driving Dogecoin's explosive rally Dan Held breaks down a theory that says Bitcoin might reach $1 million by year's end and explains why Dogecoin has become a $51 billion meme. READ MORE The billionaire scientist who developed Pfizer's breakthrough vaccine has not sold any shares in partner BioNTech's surging stock Sahin and his wife, Ozlem Tureci, are the "dream team" couple whose company partnered with Pfizer to develop and supply 3 billion vaccine doses. READ MORE Premium These 6 fintechs are rolling out crypto rewards for spending in lieu of points and miles as payment players lean into digital currencies From prize wheels to 3% Bitcoin back, here are the ways that fintechs are working crypto into their rewards programs. READ MORE Premium Clubhouse suspended a blind man for providing a live transcript to help deaf people. Disabled people say they feel excluded from the booming audio-only app. Clubhouse pledges to include "diverse people and perspectives," but the exclusive app is difficult for disabled people, especially those who are deaf. READ MORE Premium Omnicom is trying to cash in on healthcare advertising with a new data tool for clients like Pfizer and Merck Healthcare is a growing opportunity for Omnicom and other advertising holding companies. READ MORE Email sent to: aymentanaze.news@blogger.com   |   Manage preferences   |   Unsubscribe Terms of Service   |   Privacy Policy   |   © 2021 Insider Inc. 1 Liberty Plaza, New York, NY 10006